Brian MBA - Agios Pharmaceuticals CEO Director
| 8AP Stock | EUR 52.50 1.50 2.94% |
Insider
Brian MBA is CEO Director of Agios Pharmaceuticals
| Age | 54 |
| Phone | 617 649 8600 |
| Web | https://www.agios.com |
Agios Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.1813) % which means that it has lost $0.1813 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.1979) %, meaning that it generated substantial loss on money invested by shareholders. Agios Pharmaceuticals' management efficiency ratios could be used to measure how well Agios Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Larry Cordell | Origin Agritech | 56 | |
| Edward Kirnbauer | Identiv | 58 | |
| Ash Rajendra | Superior Plus Corp | N/A | |
| James Devens | Superior Plus Corp | N/A | |
| Yasheng Yang | Origin Agritech | 51 | |
| Bjorn Norrbom | SIVERS SEMICONDUCTORS AB | 72 | |
| Caroline Schlienkamp | Talanx AG | 49 | |
| Tomas Duffy | SIVERS SEMICONDUCTORS AB | 62 | |
| Steven Humphreys | Identiv | 62 | |
| Robert Smith | NMI Holdings | 53 | |
| Mike Taylor | Identiv | N/A | |
| James Kang | Origin Agritech | 54 | |
| FCA FCA | Superior Plus Corp | 68 | |
| Erik Fallstrom | SIVERS SEMICONDUCTORS AB | 56 | |
| Justin Scarpulla | Identiv | 50 | |
| Jan Wicke | Talanx AG | 55 | |
| Leigh Dow | Identiv | N/A | |
| David Bullock | Origin Agritech | 49 | |
| Torsten Leue | Talanx AG | 57 | |
| Dag Sigurd | SIVERS SEMICONDUCTORS AB | 73 | |
| Gengchen Han | Origin Agritech | 58 | |
Management Performance
| Return On Equity | -0.2 | |||
| Return On Asset | -0.18 |
Agios Pharmaceuticals Leadership Team
Elected by the shareholders, the Agios Pharmaceuticals' board of directors comprises two types of representatives: Agios Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Agios. The board's role is to monitor Agios Pharmaceuticals' management team and ensure that shareholders' interests are well served. Agios Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Agios Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| DSc FRSC, CoFounder Board | ||
| Dr DACVP, Consultant | ||
| Sarah MD, Chief RD | ||
| T Washburn, Principal Officer | ||
| Craig MD, CoFounder Board | ||
| Cecilia Jones, Chief Officer | ||
| Richa Poddar, Chief Officer | ||
| ShinSan Su, CoFounder Board | ||
| Lewis Cantley, CoFounder Board | ||
| Brian MBA, CEO Director |
Agios Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Agios Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.2 | |||
| Return On Asset | -0.18 | |||
| Operating Margin | (18.34) % | |||
| Current Valuation | 1.01 B | |||
| Shares Outstanding | 54.94 M | |||
| Shares Owned By Insiders | 1.34 % | |||
| Shares Owned By Institutions | 98.67 % | |||
| Price To Earning | (9.13) X | |||
| Price To Book | 1.62 X | |||
| Price To Sales | 159.36 X |
Currently Active Assets on Macroaxis
Other Information on Investing in Agios Stock
Agios Pharmaceuticals financial ratios help investors to determine whether Agios Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Agios with respect to the benefits of owning Agios Pharmaceuticals security.